• Caribou Biosciences reported long-term Phase 1 data for its off-the-shelf CD19 CAR-T candidate vispa-cel in second-line large B cell lymphoma.
• The results were scheduled for an oral presentation at the EHA 2026 meeting on June 12.
• Patients showed durable tumor responses, supporting the view that a single-dose, readily available cell therapy could compete with autologous CAR-T outcomes.
• Safety remained broadly manageable, with no signals that would block outpatient use, though serious events included rare treatment-related deaths.
• The update underpinned plans for the ANTLER-3 randomized Phase 3 study in about 250 patients, with progression-free survival as the primary endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.